Related Experiment Videos

[Coronary revascularization in the diabetic]

P G Steg1, D Karila-Cohen

  • 1Service de Cardiologie, Hôpital Bichat, Paris, France.

Diabetes & Metabolism
|July 28, 1999
PubMed

Insights

Diabetic patients face higher risks after balloon angioplasty. Surgery may be better than percutaneous transluminal coronary angioplasty (PTCA) for multivessel disease in diabetics, but PTCA is still needed for some cases.

Area of Science:

  • Cardiology
  • Diabetology
  • Interventional Cardiology

Context:

  • Diabetes mellitus significantly increases complication risks post-angioplasty.
  • Multivessel coronary artery disease in diabetics poses higher mortality risks with percutaneous transluminal coronary angioplasty (PTCA) compared to surgery.
  • PTCA remains a necessary revascularization option for diabetic patients with single-vessel disease or those unsuitable for surgery.

Purpose:

  • To evaluate the risks and benefits of percutaneous transluminal coronary angioplasty (PTCA) in diabetic patients.
  • To analyze the impact of diabetes on short- and long-term outcomes following coronary angioplasty.
  • To highlight the need for further research into advanced percutaneous interventions for diabetic patients.

Summary:

  • Diabetes mellitus is linked to increased short- and long-term complications after balloon angioplasty.
  • For diabetic patients with multivessel disease suitable for both surgery and PTCA, surgical revascularization may offer better long-term survival, warranting caution in routine PTCA selection.
  • Despite risks, PTCA is essential for diabetic patients with single-vessel disease or poor surgical candidacy.

Impact:

  • Findings suggest a need for careful patient selection when considering PTCA versus surgery for diabetic patients with multivessel disease.
  • Emphasizes the continued importance of PTCA for specific diabetic populations.
  • Underscores the need for further investigation into the efficacy of newer technologies like stents and glycoprotein IIb/IIIa inhibitors in diabetic patients undergoing percutaneous coronary interventions.

Related Concept Videos